Retraction notice to Cost-effectiveness of the Recombinant Zoster Vaccine among People Living with Human Immunodeficiency Virus in Japan: [VHRI Volume 44, November 2024, 101025].

This article has been retracted: please see Elsevier Policy on Article Withdrawal (https://www.elsevier.com/about/policies/article-withdrawal). This article has been retracted at the request of the authors due to an error in the study discovered after the paper was published. In this study, the cost-effectiveness of the recombinant zoster vaccine (RZV) (Shingrix®) for people living with HIV (PLWHIV) aged ≥50 years was analyzed, comparing a 2-dose RZV strategy to no RZV strategy. The initial model indicated that the no RZV strategy was more cost-effective than the 2-dose RZV strategy (Erratum to Table 2). However, an error occurred in the model, where the cost parameter for the 2-dose RZV strategy was mistakenly applied as if PLWHIV individuals received the 2-dose vaccine in every cycle, significantly inflating the cost of this strategy. Upon correcting the model to reflect that the 2-dose RZV is administered only at cycle 0, the revised results indicate that the 2-dose RZV strategy is dominant over the no RZV strategy (Erratum to Table 2). Given that this error leads to a completely reversed conclusion, this paper has been retracted.
(Copyright © 2024 International Society for Health Economics and Outcomes Research. Published by Elsevier Inc. All rights reserved.)